PASG · CIK 0001787297 · FY2025 live · 2025-12-31
Passage BIO, Inc.
View as
Model
Classic Z
FY2025
−17.72
Zone
Distress
Prior
—
Market DD
—
1y PD
—
−17.72
Z″ −39.16
Score −17.72 · distress below 1.80, grey to 2.99, safe at 3.00 and above.
Classic Z factor contributions
X1 Working capital / assets
Short-term liquidity versus the size of the balance sheet.
0.401.2 × = 0.48X2 Retained earnings / assets
Cushion from years of profits. Share buybacks can push this negative at otherwise healthy firms.
−11.321.4 × = −15.84X3 EBIT / assets
Operating return on assets. Highest weight in the original model.
−0.793.3 × = −2.61X4 Book equity / liabilities
Book equity versus the liability stack. Mega-caps often look greyer here than they would if X4 used market cap.
0.430.6 × = 0.26X5 Sales / assets
Asset turnover — how much revenue the asset base supports.
0.001 × = 0.00
Five-year path
Need two annual 10-Ks to draw a path. The desk will pull this issuer’s filings.
Meridian Rank
7.27
0–100 · Classic Z family
Book standing
4
Year change
—
Market PD
—
O-score
16
Events on this name
Same published rows as Today.
No published events on this print.
Overview
rule-v1
Passage BIO, Inc. is on classic Z at −17.72 (distress) for FY2025, from an SEC 10-K. Retained earnings / assets is the line that sets the print. This is the first live year on the desk. No market tape loaded. Classic Z was fit on manufacturers. Buybacks can send retained earnings negative at otherwise healthy issuers. X4 is book equity.
Book screen Distress; market PD —. Market PD has not been priced on this name.
Market DD · naive Merton
No market tape yet.
Pull a year of closes (Yahoo, Nasdaq if Yahoo is limited) and size equity from Nasdaq cap or EDGAR shares. Distance-to-default and 1-year PD stay blank until then.
Sector peers
Closest Classic Z scores · 7th percentile in Healthcare.
- OCGNDistressOcugen, Inc.−17.89
- ABUSDistressArbutus Biopharma Corp−17.93
- CLGNDistressCollPlant Biotechnologies Ltd−18.27
- FTHDistressFaeth Therapeutics, Inc.−17.03
- PPCBDistressPropanc Biopharma, Inc.−16.96
- ELTXDistressElicio Therapeutics, Inc.−16.90
- SNOADistressSonoma Pharmaceuticals, Inc.−18.54
- INKTDistressMiNK Therapeutics, Inc.−18.57
Filing line items
Current assets
$48M
Total assets
$62M
Current liabilities
$23M
Total liabilities
$44M
Working capital
$25M
Retained earnings
−$705M
EBIT
−$49M
Total sales
$0
Book equity
$19M
Accession 0001104659-26-022549. Live rank is the latest 10-K on EDGAR (FY2025, period 2025-12-31). Classic Z is the live score. View as is a display overlay. X4 is book equity. Pulled 13 Sept 2026.